Topotecan: weighing in when there are many options.

摘要: The manuscript by Armstrong et al. in this issue of Oncologist, reviewing the toxicity and efficacy fulldose topotecan delivered as second-line therapy individuals with small cell lung cancer or ovarian cancer, will likely serve both most comprehensive final review active agent at U.S. Food Drug Administration–approved dosage schedule. represents large, relatively homogeneous patient populations prior platinum exposure convincingly describes an activity that is comparable those all other approved drugs setting a well-defined circumscribed set toxicities. While